Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 2, 2003, Pages 554-558

  Walsh, Scott ^a   Shah, Anjali ^a   Mond, James ^a  

^a Biosynexus Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBICIN; LYSOSTAPHIN; MACROGOL;

ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BACTERICIDAL ACTIVITY; BINDING AFFINITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG HALF LIFE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TISSUE DISTRIBUTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; IMMUNOGENETICS; INJECTIONS, INTRAVENOUS; LYSOSTAPHIN; MICE; PEPTIDES; POLYETHYLENE GLYCOLS; STAPHYLOCOCCUS AUREUS;

EID: 0037311091     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.2.554-558.2003     Document Type: Article

References (17)

1. Algranati, N. E., S. Sy, and M. Modi. 1999. A branched methoxy 40-kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics of PEG-interferon alpha-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C. Hepatology 40(Suppl.):190A.
2. Climo, M. W., R. L. Patron, B. P. Goldstein, and G. L. Archer. 1998. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob. Agents Chemother. 42:1355-1360.
3. Donohue, J. H., and S. A. Rosenberg. 1983. The fate of interleukin-2 after in vivo administration. J. Immunol. 130:-2203-2208.
4. Francis, G. E., C. Delgado, and D. Fisher. 1992, PEG-modified proteins, p. 235-263. In M. C. Manning (ed.), Stability of protein pharmaceuticals: in vivo pathways of degradation and strategies for protein stabilization. Plenum Press, New York, N.Y.
5. Harrison, E. F., M. E. Fuquay, and W. A. Zygmunt. 1975. Antigenic response to topically applied proteins. Infect. Immun. 11:309-312.
6. Hinds, K., J. J. Koh, L. Joss, F. Liu, M. Baudys, and S. W. Kim. 2000. Synthesis and characterization of poly(ethylene glycol)-insulin conjugates. Bioconjug. Chem. 11:195-201.
7. Kiri, N., G. Archer, and M. W, Climo. 2002. Combinations of lysostaphin with beta-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis. Antimicrob. Agents Chemother. 46:2017-2020.
8. Patron, R. L., M. W. Climo, B. P. Goldstein, and G. L. Archer. 1999. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 43:1754-1755.
9. Quickel, K. E., Jr., R. Selden, J. R. Caldwell, N. F. Nora, and W. Schaffner, 1971. Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus. Appl. Microbiol. 22:446-450.
10. Rostin. J., A. L. Smeds, and E. Akerblom. 2000. Β-Domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol. Bioconjug. Chem. 11:387-396.
11. Schaffner, W., M. A. Melly, J. H. Hash, and M. G. Koenig. 1967. Lysostaphin: an enzymatic approach to staphylococcal disease. I. In vitro studies. Yale J. Biol. Med. 39:215-229.
12. Schiavon, O., P. Caliceti, P. Ferruti, and F. M. Veronese. 2000. Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine). Farmaco 55:264-269.
13. Tanaka, H., and T. Tokiwa. 1990. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat. Cancer Res. 50:6615-6619.
14. Tsunoda, S., T. Ishikawa, Y. Yamamoto, H. Kamada, K. Koizumi, J. Matsui, Y. Tsutsumi, T. Hirano, and T. Mayumi. 1999. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent. J. Pharmacol. Exp. Ther. 290:368-372.
15. Ueno, T., K. Ohtawa, Y. Kimoto, K. Sakurai, Y. Kodera, M. Hiroto, A. Matsushima, H. Nishimura, and Y. Inada. 2000. Polyethylene glycol-modified concanavalin A as an effective agent to stimulate anti-tumor cytotoxicity. Cancer Detect. Prev. 24:100-106.
16. Veronese, F. M. 2001. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22:405-417.
17. Zygmunt, W. A., and P. A. Tavormina. 1972. Lysostaphin: model for a specific enzymatic approach to infectious disease. Prog. Drug Res. 16:309-333.